A double-blind, placebo-controlled, clinical study examining the effect of QAW039 capsules on lung function and Astma control in non-atopic, asthmatic patients with a baseline lung function of 40-80% predicted, inadequately controlled with low dose therapy with inhaled corticosteroids The primary objective is to assess the efficacy of QAW039 (450 mg qd) compared to placebo with respect to the change in trough FEV1 from baseline to 12 weeks of post-baseline treatment in non-atopic a...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Long-term safety study of QGE031 in patients with allergic asthma who completed study CQGE031B2201 To assess long-term safety and tolerability of QGE031 given every 4 weeks s.c.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A 2-week single-blind, randomized, 3-arm proof of concept study of the effects of AIN457 (anti-IL17 antibody), ACZ885 (canakinumab, anti-IL1b antibody), or corticosteroids in patients with polymyalgia rheumatica, followed by an open label phase to assess safety and long term efficacy - To assess the efficacy of a single dose of AIN457 after 2 weeks as measured by the polymyalgia rheumatica activity score. - To assess the efficacy of a single dose of ACZ885 (canakinumab) after 2 w...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A multicenter, randomised, double-blind, placebo-controlled, parallel-group proof- of-concept study to assess the efficacy, safety and tolerability of two single i.v. infusions of AIN457 10 mg/kg (anti-IL17 monoclonal antibody) in patients with moderate to severe active Crohn’s disease Efficacy of AIN457 at 6 weeks on mean CDAI

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A phase II, multicentre study of oral LBH589 in patients with accelerated phase or blast phase (blast crisis) chronic myeloid leukemia with resistant disease following treatment with at least two BCR-ABL tyrosine kinase inhibitors To assess the hematologic response (complete hematologic response (CHR) / no evidence of leukemia (NEL) / return to chronic phase (RTC)) rate

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

An interventional study of PDR001 in patients with advanced malignancies A PDR001 I/II. fázisú vizsgálata előrehaladott stádiumú daganatos betegeknél Phase I: To estimate the RP2D and/or the MTD for PDR001 Phase II: To estimate the anti-tumor activity of PDR001

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A 12-Months, Randomized, Double-Blind, Parallel-Group, Multicenter, Proof of Concept Study of the Efficacy of Oral RAD001 (6 mg/day) versus Azathioprine and Placebo in Crohn’s Disease To demonstrate the efficacy of RAD001 in CD patients by testing the hypothesis that RAD001 6 mg/day QD is superior to AZA in maintaining patients in steroid-free remission throughout the following co-...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

2 year study of secukinumab (AIN457) treatment in patients with active Psoriatic Arthritis To demonstrate the efficacy of secukinumab 75 or 150 mg at Week 24 is superior to placebo in patients with active PsA based on the proportion of patients achieving an ACR20 response.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

To evaluate the efficacy of CAD106 and CNP520 in participants at risk for the onset of Alzheimer’s disease - To assess the effects of CAD106 and CNP520, respectively, vs. placebo on Time-to-event, with event defined as a diagnosis of MCI due to AD or dementia due to AD, whichever occurs first during the co...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Safety and Immunogenicity of Repeated Exposure to an Adjuvanted Quadrivalent Subunit Influenze Virus Vaccine Compared to Non-Adjuvanted Comparator Influenza Vaccine in Children Vaccinated in Trial V118_05 Primary Immunogenicity Objective: To evaluate the antibody responses to homologous (CBER criteria) influenza strains post vaccination with aQIV or a non-adjuvanted comparator influenza vaccine in ch...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune